Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group. Labarga P, et al. Among authors: echeverria s. J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807523 Clinical Trial.
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V; PRESCO Team. Núñez M, et al. Among authors: echeverria s. J Viral Hepat. 2008 May;15(5):363-9. doi: 10.1111/j.1365-2893.2007.00952.x. Epub 2007 Dec 21. J Viral Hepat. 2008. PMID: 18179454 Clinical Trial.
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M; PRESCO Study Group. Soriano V, et al. Among authors: echeverria s. Antivir Ther. 2007;12(4):469-76. Antivir Ther. 2007. PMID: 17668555 Clinical Trial.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V; PRESCO Study Group. Núñez M, et al. Among authors: echeverria s. AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82. doi: 10.1089/aid.2007.0011. AIDS Res Hum Retroviruses. 2007. PMID: 17725413 Clinical Trial.
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Free PMC article. Clinical Trial.
Impact of a midline catheter prioritization initiative on device utilization and central line-associated bloodstream infections at an urban safety-net community hospital.
Mena Lora AJ, Lindsey B, Echeverria S, Ali M, Krill C, Takhsh E, Bleasdale SC. Mena Lora AJ, et al. Among authors: echeverria s. Antimicrob Steward Healthc Epidemiol. 2024 Feb 16;4(1):e27. doi: 10.1017/ash.2024.21. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38415093 Free PMC article.
92 results